Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arrowhead Pharmaceuticals, Inc. - Common Stock
(NQ:
ARWR
)
74.30
+3.56 (+5.04%)
Streaming Delayed Price
Updated: 11:17 AM EDT, Jun 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 31, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Want Diversified Upside in Biotechnology? Check out LABU
March 22, 2023
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.
Via
MarketBeat
Topics
ETFs
Stocks
Analyst Ratings for Arrowhead Pharma
↗
March 21, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
↗
March 21, 2023
Via
Benzinga
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
↗
February 07, 2023
Via
Benzinga
Earnings Outlook For Arrowhead Pharmaceuticals
↗
February 03, 2023
Via
Benzinga
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
March 20, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
March 03, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
February 28, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
↗
February 15, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Arrowhead Pharmaceuticals: Here's What You Need To Know
↗
December 06, 2022
Via
Benzinga
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
↗
November 29, 2022
Via
Benzinga
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
February 15, 2023
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
February 06, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
February 06, 2023
Gainers Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54.
Via
Benzinga
Energizer, Children's Place And Other Big Stocks Moving Lower On Monday
↗
February 06, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Earnings Scheduled For February 6, 2023
↗
February 06, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion.
Via
Benzinga
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
February 02, 2023
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
January 25, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
January 09, 2023
Via
Benzinga
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
↗
January 09, 2023
Via
Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Via
Benzinga
Why Arrowhead Pharmaceuticals Stock Is Diving Today
↗
January 09, 2023
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) shares are down 20% Monday after the company announced topline results from the SEQUOIA Phase 2 study of fazirsiran in patients with
Via
Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
↗
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
December 21, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
December 21, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
December 20, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 15, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 08, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
↗
November 29, 2022
The company says it plans soon to present Phase 2 results and its Phase 3 study design.
Via
Investor's Business Daily
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
